ARTES and Minapharm sign long-term strategic development agreement

15-Jan-2008

ARTES Biotechnology and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE jointly announced the start of a strategic collaboration to develop three therapeutic proteins. Financial details were not disclosed.

ARTES will apply its proprietary Hansenula technology platform and know-how to the generation of production cell lines, analytical assay development, and lab-scale fermentation. Moreover, ARTES has granted Minapharm a commercial license option to apply its proprietary technologies to the manufacturing and marketing of these therapeutic proteins. In addition, ARTES will be responsible for the 100 L-scale production of a Minapharm protein based on an existing process using E. coli.

Minapharm will carry out the pertinent process research & development, production and commercialization of the therapeutic proteins.

The yeast strain Hansenula polymorpha is often an alternative to E. coli for producing therapeutic proteins or technical enzymes inexpensively. A number of products derived from Hansenula are already marketed worldwide such as hepatitis B vaccine, insulin, interferon alpha 2a and feed and food enzymes. Several others are in clinical trials.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances